Zacks Investment Research upgraded shares of Oasmia Pharmaceutical AB (NASDAQ:OASM) from a hold rating to a buy rating in a research note published on Tuesday morning. Zacks Investment Research currently has $3.25 price objective on the stock.

According to Zacks, “Oasmia Pharmaceutical AB is a pharmaceutical company which develops and manufactures drugs for human and veterinary oncology. Its drugs portfolio comprises Paclical, Doxophos, Docecal and OAS-19, for human treatment as well as Paccal Vet-CA1 and Doxophos Vet, for cancer treatment in dogs, which are in different clinical phases. Oasmia Pharmaceutical AB is based in Uppsala, Sweden. “

Several other equities analysts also recently weighed in on OASM. Rodman & Renshaw initiated coverage on Oasmia Pharmaceutical AB in a research report on Monday, September 12th. They set a buy rating and a $6.00 target price on the stock. HC Wainwright initiated coverage on Oasmia Pharmaceutical AB in a research report on Monday, September 12th. They set a buy rating and a $6.00 target price on the stock.

Shares of Oasmia Pharmaceutical AB (NASDAQ:OASM) traded up 0.0000% during trading on Tuesday, hitting $2.9599. Oasmia Pharmaceutical AB has a 12 month low of $2.51 and a 12 month high of $5.25. The firm’s 50 day moving average price is $2.89 and its 200-day moving average price is $3.47. The stock’s market capitalization is $105.77 million.

5 Day Chart for NASDAQ:OASM

Receive News & Stock Ratings for Oasmia Pharmaceutical AB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oasmia Pharmaceutical AB and related stocks with our FREE daily email newsletter.